RespireRx Pharmaceuticals Inc.

Symbol: RSPI




Market price today

  • -0.1239

    P/E Ratio

  • 0.0018

    PEG Ratio

  • 0.33M

    MRK Cap

  • 0.00%

    DIV Yield

RespireRx Pharmaceuticals Inc. (RSPI) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Arnold S. Lippa Ph.D.
Full-time employees:2
City:Glen Rock
Address:126 Valley Road

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

General Outlook

In simple terms, RespireRx Pharmaceuticals Inc. has 365.419 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -17.894% return, is a testament to RespireRx Pharmaceuticals Inc.'s adeptness in optimizing resource deployment. RespireRx Pharmaceuticals Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.160%. Furthermore, the proficiency of RespireRx Pharmaceuticals Inc. in capital utilization is underscored by a remarkable 0.118% return on capital employed.

Stock Prices

RespireRx Pharmaceuticals Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.001, while its low point bottomed out at $0.0008. This variance in figures offers investors a lucid insight into the roller-coaster ride that is RespireRx Pharmaceuticals Inc.'s stock market.

Liquidity Ratios

Analyzing RSPI liquidity ratios reveals its financial health of the firm. The current ratio of 0.90% gauges short-term asset coverage for liabilities. The quick ratio (0.05%) assesses immediate liquidity, while the cash ratio (0.05%) indicates cash reserves.

Current Ratio0.90%
Quick Ratio0.05%
Cash Ratio0.05%

Profitability Ratios

The effective tax rate stands at -19.84%, revealing its tax efficiency. The net income per EBT, 107.43%, and the EBT per EBIT, 128.39%, provide insights into its earnings hierarchy.

Effective Tax Rate-19.84%
Net Income per EBT107.43%
EBT per EBIT128.39%

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2037.47%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.18, we discern the balance between debt and equity financing. An interest coverage of -4.88 indicates its ability to manage interest expenses.

Debt Ratio2037.47%
Debt Equity Ratio-0.18
Total Debt to Capitalization-21.96%
Interest Coverage-4.88
Cash Flow to Debt Ratio-0.11
Company Equity Multiplier-0.01

Growth Ratios

EBIT growth, 100.00%, and operating income growth, 100.00%, offer insights into operational profitability progression. The net income growth, 100.00%, showcases bottom-line expansion, and the EPS growth, 100.00%, measures the growth in earnings per share.

EBIT Growth100.00%
Operating Income Growth100.00%
Net Income Growth100.00%
EPS Growth100.00%
EPS Diluted Growth100.00%
Weighted Average Shares Growth8.82%
Weighted Average Shares Diluted Growth8.82%
10-Year Net Income Growth per Share100.00%
5-Year Net Income Growth per Share100.00%
3-Year Net Income Growth per Share100.00%
R&D Expense Growth-100.00%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.02, and the price to book ratio, -0.02, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -1.33, and price to operating cash flows, -0.97, gauge market valuation against cash flow metrics.

Price Book Value Ratio-0.02
Price to Book Ratio-0.02
Price Cash Flow Ratio-0.97
Enterprise Value Multiple1.27
Price Fair Value-0.02
Price to Operating Cash Flow Ratio-0.97
Price to Free Cash Flows Ratio-1.33
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of RespireRx Pharmaceuticals Inc. (RSPI) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.124 in 2024.

What is the ticker symbol of RespireRx Pharmaceuticals Inc. stock?

The ticker symbol of RespireRx Pharmaceuticals Inc. stock is RSPI.

What is company IPO date?

IPO date of RespireRx Pharmaceuticals Inc. is 1989-11-06.

What is company current share price?

Current share price is 0.001 USD.

What is stock market cap today?

The market cap of stock today is 328877.000.

What is PEG ratio in 2024?

The current 0.002 is 0.002 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2.